Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX
Kaufman, J. L. (Winship Cancer Institute. Emory University)
Dimopoulos, Meletios (The National and Kapodistrian University of Athens)
White, D. (Dalhousie University and Queen Elizabeth II Health Sciences Centre)
Benboubker, L. (Service d'Hématologie et Thérapie Cellulaire. Hôpital Bretonneau. Centre Hospitalier Régional Universitaire)
Cook, G. (St James's Institute of Oncology. Leeds Teaching Hospitals National Health Service Trust and University of Leeds)
Leiba, M. (Assuta Ashdod University Hospital. Faculty of Health Science Ben-Gurion University of the Negev)
Morton, J. (Icon Cancer Care)
Joy Ho, P. (Institute of Haematology. Royal Prince Alfred Hospital)
Kim, K. (Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine)
Takezako, N. (Department of Hematology. National Hospital Organization Disaster Medical Center of Japan)
Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu)
Sutherland, H. J. (Leukemia/Bone Marrow Transplant Program. University of British Columbia)
Magen, H. (Department of Hematology Chaim Sheba Medical Center. Ramat-Gan. Sackler Faculty of Medicine. Tel Aviv University)
Iida, S. (Department of Hematology and Oncology. Nagoya City University Graduate School of Medical Sciences)
Kim, J. S. (Yonsei University College of Medicine. Severance Hospital)
Miles Prince, H. (Cabrini Hospital. Epworth HealthCare and Sir Peter MacCallum Department of Oncology. University of Melbourne)
Cochrane, T. (Gold Coast University Hospital and Griffiths University)
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Bahlis, N. J. (University of Calgary. Arnie Charbonneau Cancer Institute)
Chari, Ajai (Icahn School of Medicine at Mount Sinai)
O'Rourke, L. (Janssen Research & Development)
Trivedi, S. (Janssen Research & Development)
Casneuf, T. (Janssen Research & Development)
Krevvata, M. (Janssen Research & Development)
Ukropec, J. (Janssen Global Medical Affairs)
Kobos, R. (Janssen Research & Development)
Avet-Loiseau, Hervé (Unite de Genomique du Myelome. IUC-Oncopole)
Usmani, S. Z. (Levine Cancer Institute/Atrium Health)
San-Miguel, J. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping; patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10) was assessed via the clonoSEQ assay V2. 0. 569 patients were randomized (D-Rd, n = 286; Rd, n = 283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44. 3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18. 6 months; hazard ratio [HR], 0. 43; P < 0. 0001) and high cytogenetic risk (median: 26. 8 vs 8. 3 months; HR, 0. 34; P = 0. 0035) patients. Responses with D-Rd were deep, including higher MRD negativity and sustained MRD-negativity rates versus Rd, regardless of cytogenetic risk. PFS on subsequent line of therapy was improved with D-Rd versus Rd in both cytogenetic risk subgroups. The safety profile of D-Rd by cytogenetic risk was consistent with the overall population. These findings demonstrate the improved efficacy of daratumumab plus standard of care versus standard of care in RRMM, regardless of cytogenetic risk.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Medical research ; Cancer
Publicat a:	Blood Cancer Journal, Vol. 10 Núm. 11 (january 2020) , p. 111, ISSN 2044-5385

DOI: 10.1038/s41408-020-00375-2
PMID: 33149130

10 p, 667.7 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats